Health

Sanofi announces leadership evolution in Specialty Care Business Unit

Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity.

articleSanofi SaFebruary 17, 20269/company/sanofi-sa-1/news/sanofi-announces-leadership-evolution-in-specialty-care-business-unit-1
Sanofi announces leadership evolution in Specialty Care Business Unit

About this update from Sanofi Sa

[{"type":"text","content":"CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity.","length":302,"tagName":"p"},{"type":"text","content":"Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies.","length":370,"tagName":"p"},{"type":"text","content":"Manuela will lead Sanofi's Specialty Care Global Business Unit and serve as a member of the Executive Committee. Based in Cambridge, Mass., Manuela currently leads Sanofi's Global Immunology Alliance Franchise and oversees its worldwide strategy and performance. For more than two years, she has driven the global expansion and growth of Dupixent. With over 20 years of international healthcare experience and prior leadership roles across Specialty Care in Europe and global franchise management, Manuela brings deep operational knowledge of the business and strong familiarity with key markets and medicines. Her experience, as well as her knowledge of the company and its people, will further drive the dynamic development of Specialty Care.","length":757,"tagName":"p"},{"type":"text","content":"Olivier Charmeil, designated interim Chief Executive Officer, Sanofi, said: "I have greatly valued the opportunity to work with Brian over the years and thank him for his leadership and contributions to Sanofi. We wish him every success in the new role he has decided to pursue at this stage of his career. As we move forward, Manuela brings deep experience, longstanding commitment to Sanofi, and a thorough understanding of our Specialty Care portfolio and priorities. I am confident she will ensure strong continuity for the business while maintaining the momentum we have built and ensuring the organization continues to move with focus and speed."","length":662,"tagName":"p","attribs":{}},{"type":"text","content":"Sanofi remains committed to advancing its ...

More updates from Sanofi Sa

Specialty CareSpecialty Care Global Business UnitSanofihealthcare providerExecutive CommitteeDupixent